Elucid to Showcase PlaqueIQ™ at SCCT 2025

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques

BOSTON--(BUSINESS WIRE)--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, will be featured along with its PlaqueIQ™ image analysis software at the 20^th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), to be held July 17-20 at Palais des Congrès de Montréal.

Elucid CEO Kelly Huang, PhD, will participate in the Novel Technologies keynote session, which will be held on Friday, July 18 from 5:05 to 6:15 p.m. ET in room 210 B/F. Kelly’s presentation, “Lesion, vessel, patient, population. Anatomy, physiology, morphology: A complete picture,” will detail the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization.

Elucid will also host a breakfast symposium, “From Lesion Detail to the Patient: Getting the Entire Story with Anatomy, Physiology and Morphology,” Friday, July 18 from 7 to 7:50 a.m. ET in room 511 C/F. The session will feature two of the preeminent experts in preventative cardiology and CCTA-derived plaque morphology: Dr. Amir Ahmadi, associate professor of medicine and cardiology director, Inpatient Cardiology at Mount Sinai Fuster Heart at Morningside and Elucid lead scientific advisor, and Dr. Mark D. Berlacher, clinical cardiologist at The Christ Hospital. The session will provide a deep dive into several plaque cases using Elucid’s software and share how these findings influence treatment pathways. The program will also explore FFR_CT features on an investigational basis.¹

“The cases we will present at SCCT 2025 demonstrate the importance of moving beyond the vessel level to assess plaque at the lesion level,” said Dr. Berlacher. “Having detailed information about the amount and type of plaque at the lesion level, including lipid rich necrotic core, can help drive treatment decisions and help physicians get ahead of potentially deadly cardiac events.”

In addition to its participation in the SCCT 2025 program, Elucid will hold three dinner presentations and discussions on Thursday, July 17, Friday, July 18, and Saturday, July 19. The presentation, “CT-Guided Treatment of Coronary Artery Disease: A Step Toward Precision Medicine,” features Dr. Ahmadi, and will also include product demos.

Attendees may also participate in hands-on demos of Elucid’s flagship PlaqueIQ image analysis software, as well as its FFR_CT plaque-based algorithm (in development), in Booth 215 during exhibit hall hours. Additionally, Amy Pyke, Elucid’s senior vice president of Market Access, will host reimbursement Q&A office hours in the booth on Friday from 11:30 a.m. to 12:30 p.m. ET and Saturday from 12:30 to 1:30 p.m. ET.

PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk.

About Elucid

Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company’s PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR_CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit elucid.com.

____________________
^1	Elucid is pursuing an indication for FFRCT, derived from its plaque algorithm. This software is currently investigational and not cleared for use by the FDA.